Clinical Trials Browser

Prostatic Neoplasms × Imatinib Mesylate × Clear all

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00038194 2018-10-31

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00251225 2017-08-09

A Study of Imatinib and Docetaxel in Prostate Cancer

Phase 2 Completed

49 enrolled 7 charts

Prostatic Neoplasms

NCT01316458 2017-06-01

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Phase 2 Completed

Abdominal Neoplasms, Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT00427999 2016-11-21

INV342

Phase 2 Completed

67 enrolled 6 charts

Prostatic Neoplasms

NCT00861471 2016-06-30

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

24 enrolled 11 charts

Prostatic Neoplasms

NCT00500110 2015-04-28

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Phase 2 Completed

39 enrolled 6 charts

Prostatic Neoplasms

NCT00424385 2014-07-21

Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)

Phase 1 Completed

17 enrolled 8 charts

Prostatic Neoplasms

NCT00084825 2012-10-26

Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms

NCT00080678 2012-10-12

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Phase 2 Completed

Neoplasm Metastasis, Prostatic Neoplasms